此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of Haemodialysis Patients Switching From Aranesp to Biosimilar (SHADE)

2016年2月5日 更新者:Amgen

Retrospective Study of Stable Haemodialysis Patients Switched From Darbepoetin Alfa to Epoetin Alfa Biosimilar

The study will obtain data to show insight into clinical outcomes of patients switching from Darbepoetin Alfa to a epoetin alfa biosimilar.

研究概览

地位

完全的

条件

详细说明

Biosimilars were approved in 2007 by the EMA in EU and in 2010 by the TGA in Australia. This study will look at the retrospective data of patients that have switched from Darbepoetin Alfa to an approved epoetin alfa biosimilar. Data will be collected for the 26 week period prior to switch and a 26 week period post switch to a biosimilar. Data to be collected includes haemoglobin measurements, dose requirements, iron use, any transfusions, hospitalisations and other lab values including TSAT, Ferritin and albumin. Data from the study will be published.

研究类型

观察性的

注册 (实际的)

272

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Burgas、保加利亚、8000
        • Research Site
      • Egaleo、希腊、12242
        • Research Site
      • Egaleo, Athens、希腊、12244
        • Research Site
      • Kallithea, Athens、希腊、17676
        • Research Site
      • Larissa、希腊、41335
        • Research Site
      • Patra、希腊、26500
        • Research Site
      • Patra、希腊、26225
        • Research Site
      • Lemgo、德国、32657
        • Research Site
      • Lich、德国、35423
        • Research Site
      • Minden、德国、32429
        • Research Site
      • Milazzo ME、意大利、98057
        • Research Site
      • Pisa、意大利、56124
        • Research Site
      • Chojnice、波兰、89-600
        • Research Site
      • Gdansk、波兰、80-952
        • Research Site
      • Krakow、波兰、31-501
        • Research Site
      • Lublin、波兰、20-954
        • Research Site
      • Poznan、波兰、60-355
        • Research Site
      • Rybnik、波兰、44-200
        • Research Site
    • Queensland
      • Herston、Queensland、澳大利亚、4029
        • Research Site
      • Nambour、Queensland、澳大利亚、4560
        • Research Site
      • Woolloongabba、Queensland、澳大利亚、4102
        • Research Site
    • Andalucía
      • Jaen、Andalucía、西班牙、23007
        • Research Site
    • Castilla León
      • Zamora、Castilla León、西班牙、49022
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

The study population comprises prevalent haemodialysis (HD) patients treated at EU and Australian dialysis clinics after September 2008. Eligible patients will have received treatment with darbepoetin alfa for at least 26 weeks prior to being converted to an EMA/TGA-approved epoetin alfa biosimilar. At each participating study site, all potentially eligible patients are to be considered for enrolment.

描述

Inclusion Criteria

  • Patients ≥18 years of age
  • Patients with CKD on haemodialysis and fulfilling the following:

    • Received HD for at least 26 weeks prior to switching from treatment with darbepoetin alfa to treatment with an EMA/TGA-approved epoetin alfa biosimilar
    • Received darbepoetin alfa treatment i.v. for at least 26 weeks immediately prior to switching to an EMA/TGA-approved epoetin alfa biosimilar (breaks due to treatment being intentionally withheld are permitted)
    • Switched from darbepoetin alfa treatment to an EMA/TGA-approved epoetin alfa biosimilar at least 26 weeks prior to enrolment
    • Received at least one dose of an EMA/TGA-approved epoetin alfa biosimilar after switching from darbepoetin alfa treatment
  • Mean monthly Hb 10-12g/dL in the 12 weeks prior to switch
  • Stable darbepoetin alfa dose (i.e. no more than one increment or decrement of PFS) in the 12 weeks prior to switch
  • Patient or patient's legally acceptable representative has provided informed consent, if applicable according to local requirements

Exclusion Criteria:

  • Treatment with an ESA other than darbepoetin alfa during the 12 weeks prior to switch to biosimilar
  • More than 14 days' cumulative treatment with short-acting ESA during weeks 26-13 prior to switch to biosimilar
  • Subject received chemotherapy or major surgery during the 26 weeks prior to switch to biosimilar
  • Subject was enrolled in an interventional device or drug study at any time during the 52-week data observation period or within 30 days prior to commencement of the data observation period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
队列 1
慢性肾病患者

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Haemoglobin Concentration
大体时间:Duration of observation period -52 weeks
Mean haemoglobin concentration over time
Duration of observation period -52 weeks

次要结果测量

结果测量
措施说明
大体时间
ESA Doses
大体时间:Duration of observation period -52 weeks
Doses of ESA over time.
Duration of observation period -52 weeks
Dose ratio
大体时间:Start post-switch (weeks 1-4) and pre-switch (weeks -4--1)
Dose ratio between the start of the post-switch observation period and pre-switch
Start post-switch (weeks 1-4) and pre-switch (weeks -4--1)
Dose ratio
大体时间:Between end of post-switch (weeks 23-26) and pre-switch (weeks -4--1)
Dose ratio between the end of the post-switch observation period and pre-switch
Between end of post-switch (weeks 23-26) and pre-switch (weeks -4--1)
Haemoglobin excursions
大体时间:Duration of observation period -52 weeks
Haemoglobin excursions (<10/dL and >12g/dL)
Duration of observation period -52 weeks
Haemglobin within range
大体时间:Duration of observation period -52 weeks
Haemoglobin in the range 10-12g/dL over time
Duration of observation period -52 weeks
TSAT, ferritin and albumin values
大体时间:Duration of observation period -52 weeks
TSAT, ferritin and albumin over time
Duration of observation period -52 weeks
Iron Use
大体时间:Duration of observation period -52 weeks
Iron use (dose/route) over time
Duration of observation period -52 weeks
Red cell transfusions (including number of units transfused)
大体时间:Duration of observation period -52 weeks
Red cell transfusions (including number of units transfused)
Duration of observation period -52 weeks
Hospitalisations (including primary cause)
大体时间:Duration of observation period -52 weeks
Hospitalisations (including primary cause)
Duration of observation period -52 weeks

其他结果措施

结果测量
措施说明
大体时间
Number of Subjects with PRCA testing and incidence of neutralizing anti-erythropoietin antibodies
大体时间:Duration of 52-week observation period
Pure Red Cell Aplasia (PRCA) test and results
Duration of 52-week observation period

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年6月1日

初级完成 (实际的)

2015年4月1日

研究完成 (实际的)

2015年5月1日

研究注册日期

首次提交

2014年7月7日

首先提交符合 QC 标准的

2014年7月14日

首次发布 (估计)

2014年7月16日

研究记录更新

最后更新发布 (估计)

2016年2月8日

上次提交的符合 QC 标准的更新

2016年2月5日

最后验证

2016年2月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅